These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 33685778)

  • 1. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
    Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
    Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
    Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next generation yellow fever vaccine induces an equivalent immune and transcriptomic profile to the current vaccine: observations from a phase I randomised clinical trial.
    Pagnon A; Carre C; Aguirre M; Chautard E; Gimenez S; Raynal F; Feroldi E; Scott P; Modjarrad K; Vangelisti M; Mantel N
    EBioMedicine; 2024 Oct; 108():105332. PubMed ID: 39293214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes.
    Bellone R; Mousson L; Bohers C; Mantel N; Failloux AB
    PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010930. PubMed ID: 36516120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate.
    Esson R; Rodrigues De Sousa E; Benair L; Devard N; Soulet D; Gillet A; Bassard I; Falque S; Chareyre A; Marmin M; Girerd-Chambaz Y; Logvinoff C; Navarro Sanchez ME
    Vaccine; 2022 Sep; 40(38):5641-5650. PubMed ID: 36028455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial.
    Modjarrad K; Scott PT; McCauley M; Ober-Shepherd B; Sondergaard E; Amare MF; Parikh AP; Omar B; Minutello AM; Adhikarla H; Wu Y; P AR; Delore V; Mantel N; Morrison MN; Kourbanova KS; Martinez ME; Guzman I; Greenleaf ME; Darden JM; Koren MA; Hamer MJ; Lee CE; Hutter JN; Peel SA; Robb ML; Vangelisti M; Feroldi E
    Lancet Infect Dis; 2024 Aug; ():. PubMed ID: 39153488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model.
    Amanna IJ; Thomas A; Engelmann F; Hammarlund E; Raué HP; Bailey AL; Poore EA; Quintel BK; Lewis AD; Axthelm MK; Johnson AL; Colgin LMA; Diamond MS; Messaoudi I; Slifka MK
    Cell Rep Med; 2024 Jul; 5(7):101655. PubMed ID: 39019010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
    Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
    Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of inactivated cultural yellow fever vaccine].
    Ivanov AP; Klebleeva TD; Rogova YV; Ivanova OE
    Vopr Virusol; 2020 Sep; 65(4):212-217. PubMed ID: 33533224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
    Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
    mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.
    Tottey S; Shoji Y; Jones RM; Chichester JA; Green BJ; Musiychuk K; Si H; Manceva SD; Rhee A; Shamloul M; Norikane J; Guimarães RC; Caride E; Silva ANMR; Simões M; Neves PCC; Marchevsky R; Freire MS; Streatfield SJ; Yusibov V
    Am J Trop Med Hyg; 2018 Feb; 98(2):420-431. PubMed ID: 29231157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells.
    Palmer DR; Fernandez S; Bisbing J; Peachman KK; Rao M; Barvir D; Gunther V; Burgess T; Kohno Y; Padmanabhan R; Sun W
    J Gen Virol; 2007 Jan; 88(Pt 1):148-156. PubMed ID: 17170447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.